Citations 13
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Lee, Stephanie J. , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Bunworasate, Udomsak , Efebera, Yvonne A. , Ferrara, James L.M. , Pidala, Joseph, Howard, Alan , Wu, Juan , Bolaños‐Meade, Javier , Ho, Vincent T. , Alousi, Amin, Weisdorf, Daniel J. , MacMillan, Margaret L. , Weisdorf, Dan , Levine, John E , Holtan, Shernan , DeFor, Todd E. , Panoskaltsis‐Mortari, Angela , Flowers, Mary E.D. , Chen, George L. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Howard, Alan, Alousi, Amin Majid , Blazar, Bruce R. , Lee, Stephanie J , Wood, William A
Blood Advances | August 28, 2018 | Volume: 2 | Issue: 15 | Pages: 1882-1888
10.1182/bloodadvances.2018017343
Key PointsHigh-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Shah, Nirav N. , Ahn, Kwang Woo , Litovich, Carlos, Fenske, Timothy S. , Ahmed, Sairah , Bejanyan, Nelli , Bolaños‐Meade, Javier , Chen, Andy I. , Ciurea, Stefan O. , Bachanová, Veronika , DeFilipp, Zachariah , Epperla, Narendranath , Farhadfar, Nosha , Herrera, Alex F. , Haverkos, Bradley M. , Holmberg, Leona , Hossain, Nasheed , Kharfan‐Dabaja, Mohamed A. , Kenkre, Vaishalee P. , Murthy, Hemant S. , Rezvani, Andrew R. , D’Souza, Anita , Ulrickson, Matthew L. , Waller, Edmund K. , Sureda, Anna , Smith, Sonali M. , Holmberg, Leona , Chen, Andy , Kharfan-Dabaja, Mohamed A., D'Souza, Anita , Bachanova, Veronika , Murthy, Hemant S , Waller, Edmund K , Epperla, Narendranath , Ahmed, Sairah , Battiwalla, Minoo , Dahi, Parastoo B , Lazarus, Hillard M. , Nishihori, Taiga , Savani, Bipin N. , Hamadani, Mehdi
Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940
10.1182/bloodadvances.2018018531
Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Smith, Sonali M. , Godfrey, James , Ahn, Kwang Woo , Digilio, Alessandro, Ahmed, Sairah , Bachanová, Veronika , Bashey, Asad, Bolaños‐Meade, Javier , Cairo, Mitchell S. , Chen, Andy , Copelan, Edward A. , Aljurf, Mahmoud , Farooq, Umar , Ganguly, Siddhartha , Holmberg, Leona , Inwards, David J. , Kanate, Abraham S. , Karmali, Reem , Kenkre, Vaishalee P. , Kharfan‐Dabaja, Mohamed A. , Klein, Andreas K. , Mei, Matthew , Geethakumari, Praveen Ramakrishnan , Saad, Ayman , Schouten, Harry C. , Shah, Nirav N. , Urbano-Ispizúa, Álvaro , Vij, Ravi , Sureda, Anna , Holmberg, Leona , Bachanova, Veronika , Inwards, David, Mussetti, Alberto , Savani, Bipin N , Sureda, Anna , Hamadani, Mehdi , Chen, Andy I. , Saad, Ayman , Mei, Matthew , Farooq, Umar , Ahmed, Sairah , Karmali, Reem , Agrawal, Vaibhav , Bacher, Ulrike , Chhabra, Saurabh , Dahi, Parastoo B , Hertzberg, Mark , Lazarus, Hillard M. , Mussetti, Alberto , Nishihori, Taiga , Savani, Bipin N. , Vose, Julie M. , Hamadani, Mehdi
Cancer | April 12, 2018 | Volume: 124 | Issue: 12 | Pages: 2541-2551
BACKGROUNDEarly treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.METHODSThis study compared autologous hematopoietic stem cell transplantation (auto‐HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo‐HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto‐HCT or allo‐HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression‐free survival, relapse, and nonrelapse mortality (NRM).RESULTSFour hundred forty FL patients had ETF (auto‐HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow‐up of 69 to 73 months, the adjusted probability of 5‐year OS was significantly higher after auto‐HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P = .0008). The 5‐year adjusted probability of NRM was significantly lower for auto‐HCT (5%) versus MSD (17%) or MUD HCT (33%; P < .0001). The 5‐year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto‐HCT (58%; P < .0001).CONCLUSIONSPatients with high‐risk FL, as defined by ETF, undergoing auto‐HCT for FL have low NRM and a promising 5‐year OS rate (70%). MSD HCT has lower relapse rates than auto‐HCT but similar OS. Cancer 2018;124:2541‐51. © 2018 American Cancer Society.